Mereo BioPharma Group plc

As of June 30, 2026, Mereo BioPharma Group plc Sponsored ADR carries a market capitalization of 51.32M, placing it among publicly traded companies globally. Its enterprise value stands at 22.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mereo BioPharma Group plc Sponsored ADR's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Mereo BioPharma Group plc Sponsored ADR has 159.62M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Mereo BioPharma Group plc Sponsored ADR maintains a current ratio of 5.88, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.59, indicating elevated leverage, while an interest coverage ratio of -422.00 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Mereo BioPharma Group plc Sponsored ADR posted a negative return on equity (ROE) of -39.45, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -34.04, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 39.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Mereo BioPharma Group plc Sponsored ADR's stock has declined approximately 85.40% over the past 52 weeks. The 50-day moving average sits at 0.31, while the 200-day moving average is 0.34.

Over the twelve months ended June 30, 2026, Mereo BioPharma Group plc Sponsored ADR generated - - in revenue and converted that into -13.72M in net income, yielding earnings per share of -0.09. EBITDA reached -15.19M, while operating income came in at -15.58M.

As of June 30, 2026, Mereo BioPharma Group plc Sponsored ADR holds 30.12M in cash and equivalents against 1.03M in total debt, resulting in a net debt position of -30.12M. Total book value stands at 28.65M, with working capital of 27.72M providing operational flexibility.

Mereo BioPharma Group plc Sponsored ADR produced -10.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -300,000.00 in capital expenditures, free cash flow totaled -10.65M - equivalent to -0.07 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -20.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Mereo BioPharma Group plc Sponsored ADR shareholders.

As of June 30, 2026, Mereo BioPharma Group plc Sponsored ADR has an Altman Z-Score of -16.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.